LC KILLS MORE PEOPLE THAN BREAST,
PROSTATE, COLON, LIVER, MELANOMA,
AND KIDNEY CANCERS COMBINED.

 

Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer

September 24th, 2007

xyotax.jpgTrial Lays Road Map for Potential Approval of XYOTAX(R) for Women with Advanced Non-Small Cell Lung Cancer

 

Posted in Non-Small-Cell, Research, Treatment by Debi

Trackback

 
«
»

Leave a Reply